Dry AMD and Wet AMD: What You Need to Know
How Dry AMD Develops
Dry AMD is by far the more common form of the disease, and it tends to progress slowly over months or years. Understanding how it develops and what it does to your vision can help you stay ahead of it.
Dry AMD develops when the macula, the small central part of the retina responsible for sharp, detailed vision, gradually thins over time. Small yellow protein deposits called drusen build up beneath the retinal pigment epithelium (the supportive cell layer under the retina). As these changes accumulate, the light-sensitive cells in the macula begin to break down.
Dry AMD is classified into three stages that reflect how much the disease has advanced.
- Early dry AMD features small drusen with no noticeable vision symptoms
- Intermediate dry AMD involves medium to large drusen and may cause mild blurring, especially in dim light
- Late dry AMD, called geographic atrophy, occurs when patches of retinal tissue break down and create permanent blind spots in central vision
Not everyone with early dry AMD will reach the late stage. Regular monitoring makes a meaningful difference in catching changes early.
Vision loss from dry AMD is typically gradual, unfolding over months or years. You may find you need brighter light to read comfortably, have more difficulty adjusting between bright and dim environments, or notice mild blurriness in the center of your visual field. Because these changes can be subtle, many people do not realize how much their vision has changed until a comprehensive eye exam reveals the progression.
How Wet AMD Develops
Wet AMD is less common than dry AMD, but it causes vision loss far more quickly and can become serious within days to weeks. Knowing its signs and understanding why rapid treatment matters can help preserve your sight.
Wet AMD develops when abnormal blood vessels grow from beneath the retina into the macula, a process called choroidal neovascularization. These fragile vessels leak blood and fluid, which rapidly damages the macula. Although wet AMD accounts for a smaller percentage of AMD cases overall, it is responsible for the majority of severe vision loss caused by the disease.
Unlike dry AMD, wet AMD can cause noticeable changes very quickly. Straight lines may appear wavy or bent, a symptom called metamorphopsia. A dark or blank spot may form in the center of your vision. Colors may look washed out or faded. These changes can occur in one eye while the other remains unaffected, which makes them easier to miss unless you regularly check each eye separately.
Any stage of dry AMD can convert to wet AMD at any time. Wet AMD is always considered late-stage disease, regardless of what stage of dry AMD preceded it. This is why daily home monitoring is recommended for all AMD patients. If you notice new distortion or a sudden dark spot, contact your eye care provider the same day, not at your next scheduled appointment.
Treatment Options for Dry AMD
Treatment for dry AMD depends on what stage the disease has reached. While there is currently no treatment that reverses damage already done, there are meaningful options for slowing progression at each stage.
For patients with intermediate dry AMD, a specific high-dose vitamin and mineral formula known as AREDS2 has been shown to meaningfully reduce the risk of progression to advanced AMD. Your specialist can confirm whether you are a good candidate for these supplements based on your stage of disease. AREDS2 is not recommended for early dry AMD, where the benefit has not been established.
Geographic atrophy is the late stage of dry AMD, and two FDA-approved medications are available to help slow the expansion of damaged retinal tissue. These complement inhibitors, pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay), are delivered by injection into the eye at regular intervals. Neither medication restores lost vision or improves visual acuity, but both have been shown to reduce the rate at which geographic atrophy spreads. Patients receiving these treatments require close monitoring for signs of wet AMD conversion, which can occur as a side effect.
Photobiomodulation, a form of light therapy delivered to the retina, has received FDA authorization for dry AMD. Clinical trial data has shown improvements in visual acuity in patients with intermediate dry AMD compared to a sham treatment. Your specialist can help determine whether this option is appropriate for your individual situation.
Treatment Options for Wet AMD
Wet AMD requires prompt intervention. The treatments available today are effective at slowing or stopping damage, but the window for preserving vision is narrow. Early action gives patients the best possible outcome.
The primary treatment for wet AMD is anti-VEGF therapy, which stands for anti-vascular endothelial growth factor. A retina specialist injects medication directly into the eye to block the signal that drives abnormal blood vessel growth. Available medications include ranibizumab, aflibercept, bevacizumab, and faricimab. Many patients stabilize their vision or experience some improvement with consistent treatment. Delaying treatment can result in permanent central vision loss that cannot be recovered.
Faricimab is a newer bispecific antibody that targets two pathways involved in abnormal vessel growth, VEGF-A and angiopoietin-2. For some patients with wet AMD, faricimab allows dosing intervals of up to four months, which is longer than earlier anti-VEGF medications required. This can reduce the number of office visits and injections needed over time while maintaining control of the disease. Your retina specialist will determine the right medication and schedule based on how your eye responds to treatment.
Lifestyle Strategies for Both Forms
No lifestyle change can reverse AMD, but several well-supported habits can meaningfully reduce your risk of progression and support your overall eye health over time.
Smoking is one of the strongest modifiable risk factors for AMD. It roughly doubles the risk of developing advanced AMD and accelerates progression in both the dry and wet forms of the disease. Quitting at any age provides benefit, and the sooner you stop, the better the potential impact on your eye health.
A Mediterranean-style eating pattern, one rich in dark leafy greens, yellow and orange vegetables, and fatty fish, is associated with better outcomes in AMD. Managing blood pressure and cholesterol also matters, since cardiovascular health and macular health are closely connected. Regular aerobic exercise supports both. These factors help reduce the oxidative stress and inflammation that drive damage in both dry and wet AMD.
The Amsler grid is a simple home tool that can help you detect early changes in your central vision. Hold the grid at reading distance, cover one eye, and look directly at the center dot. If any lines appear wavy, bent, or missing, or if you notice a new dark area, contact your eye care provider the same day. Checking each eye separately every day gives you the best chance of catching a dry-to-wet conversion early enough to act on it.
Frequently Asked Questions
These are some of the questions we hear most often from patients navigating an AMD diagnosis.
Yes, and this is not uncommon. Each eye can be at a different stage of the disease or even a different form entirely. This is one reason your eye care provider monitors and documents each eye independently during every visit. If one eye has already converted to wet AMD, the other eye is at higher risk and should be watched closely with daily Amsler grid checks.
Wet AMD should be evaluated urgently, ideally on the same day you notice new symptoms such as sudden distortion or a dark spot in your vision. Vision loss from wet AMD can advance rapidly, sometimes within days to weeks. The sooner anti-VEGF treatment begins after wet AMD is confirmed, the greater the likelihood of stabilizing or recovering some of the affected vision.
Anti-VEGF injections are not used to treat dry AMD in its typical form. They are specifically designed to block the abnormal blood vessel growth that defines wet AMD. For dry AMD, the appropriate options depend on stage, ranging from lifestyle measures and AREDS2 supplements for intermediate disease to complement inhibitors for geographic atrophy. Your specialist can explain which approach fits your diagnosis.
AMD affects only central vision, not peripheral (side) vision. This means most patients retain enough peripheral vision to move around their environment safely. However, the central vision loss caused by AMD makes detailed tasks such as reading, recognizing faces, and driving significantly more difficult or eventually impossible without the use of low-vision aids.
The answer depends on your stage and form of AMD. Patients with wet AMD receiving injections are typically seen at each treatment visit, and sometimes more frequently when treatment is being adjusted. Patients with dry AMD are usually monitored every six to twelve months, but that schedule may be shortened if your disease is progressing. Your specialist will set a follow-up plan based on your individual situation, and home Amsler grid monitoring supplements your in-office care between appointments.
Yes. Geographic atrophy is a serious stage of dry AMD, but active management still matters. FDA-approved complement inhibitors can slow the growth of the affected area. Staying consistent with lifestyle habits, monitoring for wet AMD conversion, and working with a low-vision specialist if needed are all meaningful steps. Losing some central vision does not mean the situation is beyond care.
Expert AMD Care at Rhode Island Eye Institute
At Rhode Island Eye Institute, our retina specialists, Dr. Gaurav Gupta and Dr. Pranjal Thakuria, bring subspecialty training and advanced diagnostic technology to the evaluation and treatment of both dry and wet AMD. Whether you are newly diagnosed or managing a condition that has been with you for years, we are here to guide you with clarity, precision, and genuine concern for your long-term vision. We invite you to schedule an appointment and take an active role in protecting what matters most to you.